Zymeworks Inc. (ZYME) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. This is the conference operator. Welcome to ZOMWorks second quarter 2025 results conference call and webcast. As a reminder, all participants are in listen-only mode, and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. To ask a question, please press star 1 and 1 on your telephone keypad. I would now like to turn the conference over to Trinnell and Amdur. Senior Director of Investor Relations. Please go ahead. Thank you, Operator, and good afternoon, everyone. Thanks for joining our second quarter 2025 results conference call. Before we begin, I'd like to remind you that we'll be making a number of forward-looking statements during this call, including, without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary. Forward-looking statements are based upon our current expectations and various assumptions. and are subject to the usual risks and uncertainties associated with companies in our industry and at our stage of development. The discussion of these risks and uncertainties will refer you to the latest SPC filings as found on our website and as part of the SPC. In a moment, I will hand over to Yoni Patterson, our Executive Vice President and Chief Business and Financial Officer, who will provide an overview of our recent business and partnership updates, along with financial results for our second quarter 2025. Following this, Dr. Sabine McCann, our Senior Vice President of Clinical Development, will provide progress updates on our phase 1 programs, DW1-1 and DW1-1. We will then pass the call over to Dr. Paul Moore, our Chief Scientific Officer, who will give an overview of recent R&D developments, as well as an update on IMD cl...